DocumentsDate added
Original article
Yanka Karamalakova1,*, Krishna Chuttani2, Rakesh K. Sharma3, Veselina Gadjeva4, Antoaneta Zheleva5 and Anil K. Mishra6
Affiliation:
1. Assistant professor*; Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
2. Assistant professor; Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences,Brig. S.K Mazumdar Marg, Delhi-110054, India
3. Professor; Institute of Nuclear Medicine and Allied Sciences, Brig S. K. Mazumdar Marg, Delhi-110054, India
4.Professor; Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
5. Professor; Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
6.Professor; Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences,Brig. S.K Mazumdar Marg, Delhi-110054, India
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
2. Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S.K Mazumdar Marg,Delhi-110054, India
Address reprint requests to
Yanka Karamalakova
Scientist and Assistant Professor, Electron Paramagnetic Resonance Laboratory, Department of Chemistry and Biochemistry, Str Armaiska 11, Medical Faculty, Trakia University, Stara Zagora- 6000, BULGARIA
Article citation:
Karamalakova Y, Chuttani K, Sharma R, Gadjeva V, Gadjeva A, Mishra A. Nitroxyl-Labeled Glycine Containing 2-Chlorethylnitrosourea: A study of 99mTc-Radiolabeling, EPR spectroscopy and biological evaluation of new potential anticancer agent for tumor imaging and radiotherapy. J Pharm Biomed Sci. 2015; 05(04):317-327. Available at www.jpbms.info
ABSTRACT:
Recently, a new class of in vitro and ex vivo radiotracers/radioprotectors, the nitroxyl–labeled agent N-[N'-(2-chloroethyl)-N’-nitrosocarbamoyl-glycine amide of 2,2,6,6-tetramethyl-4-aminopiperidine-1-oxyl (SLCNUgly), has been discovered. Our previous investigations demonstrated that SLCNUgly is a low-molecular-weight stable free radical which is freely membrane permeable, easily crosses the blood brain barrier and exhibited in/ex vivo the lowest general toxicity and higher anticancer activity against some experimental tumor models. Further investigation was aimed to develop a 99mTc-labeled SLCNUgly (96.5%) as a chelator and evaluate its labeling efficiency and potential use as a tumor seeking agent and for early diagnosis. Tissue biodistribution of 99mTc- SLCNUgly was determined in normal mice at 1, 2, and 24 h (n=4/ time interval, route of administration i.v.). The distribution data was compared to that using male albino non-inbred mice and EPR investigation. The imaging characteristics of 99mTc– SLCNUgly conjugate examined in Balb/c mice grafted with Ehrlich Ascitis tumor in the thigh of hind leg demonstrated major accumulation of the radiotracer in organs and tumor. Planar images and auto-radiograms confirmed that the tumors could be visualized clearly with 99mTc- SLCNUgly. Blood kinetic study of radio-conjugate showed a biexponential pattern, as well as quick reduced duration from the blood circulation. This study establishes Glycine Containing nitroxyl (SLCNUgly) as a new spin-labeled diagnostic marker which reduce the negative lateral effects of radiotherapy and for tumor- localization.
KEYWORDS: SLCNUgly, Ex Vivo EPR, 99mTc-conjugate, Biodistribution, EAT Tumor Imaging
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of support: The research work was funded by the Institute of Nuclear Medicine and Allied Sciences, New Delhi, India (BIn–7/2008).
REFERENCES
1. Eary JF, Press OW. High dose radioimmunotherapy in malignant lymphoma. Recent Results Cancer Res. 1996; 141:177–182.
2. De Nardo G, Malik E, Whitec CA, Wisemand G, De Nardoa S. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001; 39 (1-2): 203-218.
3. Humblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardr SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004; 10: 7063-7070.
4.Theobald AE. Theory and practice. Sampson CB, ed. Text-book of Radiopharmacy. New York, NY: Gorden and Breach. 1990; 127-128.
5. Saha GB. Methods of radiolabeling. Physics and Radiobiology of Nuclear Medicine. New York, NY: Springer-Verlag. 1993; 100-106.
6. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999; 99: 2235-2268.
7. Arulsudar N, Subramanian N, Mishra P, Chuttani K, Sharma RK, Murthy RSR. Preparation, Characterization, and Biodistribution Study of Technetium-99m -Labeled Leuprolide Acetate-Loaded Liposomes in Ehrlich Ascites Tumor-Bearing Mice. AAPS Pharm Sci. 2004; 6(1): Article 5;1_12.
8. Chuttani K, Mishra P, Chopra M, Panwar P, Sharma RK, Mishra AK. Radiolabelling and Biological Evaluation of a non—peptidic compound from Terminalia chebula (Harar) for CCK Expressing Tumours. IJNM. 2003; 18: 19-24.
9. Gadzheva V, Zheleva A, Raikova E. Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on DOPA-oxidase activity of tyrosinase. Cancer Biochem Biophys. 1999; 17(1-2): 99-108.
10. Gadzheva V, Koldamova R. Spin-labeled 1-alkyl-1–nitrosourea synergists of antitumor antibiotics. Anti-cancer Drug Design. 2001; 16 (4-5): 247-253.
11.Tang Wei-Ci and Eisenbrand G. Synthesis of potentialantineoplastic derivatives 0f N-[N-(2-chloroethyl)-N’-nitrosocarbamoyl]-amino asids. Arch. Pharm. (Weinhein). 1981; 314: 910-917.
12. Tsujihara K, Ozeki M, Morikawa T, Kavamori M, Akaike Y, and Arai Y. A new class of nitrosoureas. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas. J.Med. Chem. 1982; 25: 441-446.
13. Berger MR, Floride J, Schreiber J, Schmähl D, and Eisenbrand G. Short term anticancer efficacy in methyl nitrosourea induced rat mammary carcinoma and hormonal activity in mice. Cancer Res. Clin. Oncol. 1984; 108: 148-153.
14. Roger P, Monneret C, Fournier JP, Choay P, Garnet R, Gosse Ch, Letourneux Y, Atassi Ch, Gouyette A. Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars. J. Med Chem. 1989; 32(1): 16-23. 15. Konieczny M, Sosnovsky G, Gutierrez P. In the search for new anticancer drugs, I. Antitumor activity of various nitroxyl- and aziridine-containing phosphorus compounds. Z. Naturforsch. 1981; 36b: 888-891.
16. Gutierrez P., Konieczny M., Sosnovsky G., In the search for new anticancer drugs, II. Antitumor activity, toxicity and electron spi n resonance of spin labeled Thio TEPA derivatives. Z. Naturforsch., 1981; 36b: 1612-1617.
17. Raikov Z., Todorov D., Ilarionova M., Demirov G., Tsanova T., Kafalieva D. Synthesis and study of spin-labeled nitrosoureas. Cancer Biochem Biophys. 1985; 7(4): 343-348.
18. Sosnovsky G, Li SW. In the search for new anticancer drugs XII. Synthesis and biological evaluation of spin labelled nitrosoureas. Life Science, 1985; 36 (15): 1479-1483.
19. Zheleva A, Raikov Z, Ilarionova M, and Todorov D. Spin labeled amino acid nitrosourea derivatives - synthesis and antitumour activity. Pharmazie. 1995; 50: 25-26.
20. Zheleva A, Raikov Z, Ilarionova M, Carpenter B, Todorov D, Armstrong N. Potential antimelanomic drugs 1. Synthesis and antimelanomic effect of a spin labeled D,L-amino acid containing a 2-chloroethylnitrosocarbamoyl group. Pharmazie. 1996; 51: 602-604.
21. Gadjeva V, Raikov Z. Syntheses and antitumor activity of 4-{N-[N-(2-chloroethyl)-N-nitrosocarbamoyl]hydrazono}-2,2,6,6-tetramethylpiperidine-1-oxyl. Die Pharmazie. 1999; 54(13) 79.
22. Zheleva A, Gadjeva V. Spin-labeled nitrosoureas and triazens and their nonlabeled clinically used analogues- a comperative study on their physicochemical properties and antimelanomic effecst. Int. J. Pharmaceutics. 2001; 212: 257- 266.
23. Gadjeva V, Ichimory K, Nakazawa H, Raikov Z. Superoxide scavenging activity of spin-labeled nitrosourea and triazene derivatives. Free Radical Res. 1994; 21(3): 177-186.
24. Ilarionova MV, Zheleva AM, Raikov ZD, Todorov DK, Dudov AP. Nitrosourea antitumor agents correlation between antitumor action and some biochemical properties of newly synthesized derivatives. J. Chemotherapy. 1993; 5 (N1): 786-787.
25. Zheleva A, Stanilova S, Dobrva Z, Zhelev Z. Two glycine containing 2-chloroethylnitrosoureas - a comperative study on some physicochemical properties, in vivo antimelanomic effects and immunomodulatory properties. Int. J. Pharmaceutics. 2001; 222: 237- 242.
26. Matsumoto K, Hyodo F, Matsumoto A, Koretsky AP, Sowers AL, Mitchell JB, and Krishna MC. High resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res. 2006; 12: 2455–2462.
27. Zweier JL, Kuppusamy P. Electron paramagnetic resonance measurements of free radicals in the intact beating heart: a technique for detection and characterization of free radicals in whole biological tissues. Proc. Natl. Acad. Sci. 1988; 85: 5703–5707.
28. Zhelev Z, Bakalova R, Aoki I, Matsumoto K, Gadjeva V, Anzai K, Kanno I. Nitroxyl radicals as low toxic spin-labels for non-invasive magnetic resonance imaging of blood-brain barrier permeability for conventional therapeutics. Chem Commun (Camb). 2009; 7:53-55.
29. Chen XJ, Li L, Liu F, Liu BL. Synthesis and biological evaluation of technetium-99m labeled deoxy glucose derivatives as imaging agents for tumor. Med. Chem. Lett. 2006; 16: 5503-5506.
30. Ilgan S, Yang DJ, Higuchi T, Zareneyrizi F, Bayhan H, Yu D, Kim EE, Podoloff DA. 99mTc-ethylenedicysteine- folate: A new tumor imaging agent, synthesis, labeling, and evaluation in animals. Cancer Biother Radioph. 1998; 6: 427.
31. Richardson VJ, Jeyasingh K, Jewkes RF. Properties of [99mTc] technetium labeled liposomes innormal and tumor bearing rats. Biochem Soc Trans. 1977; 5: 290-291.
32. Halpern HJ, Spencer DP, Polen JV, Bowman MK, Nelson AC, Dowey EM, Teicher BA. Imaging radio frequency electron spin resonance spectometer with high resolution and sensitivity for in vivo mesurements. Rev Sci Instrum. 1989; 60: 1040–1050.
33. Simeonova M, Ivanova T, Raikov Z, Konstantinov H. Tissue distribution of polybutylcyanoacrylate nanoparticles loaded with spin-labeled nitrosourea in Lewis lung carcinoma-bearing mice. Acta Physiol Pharmacol Bulgaria. 1994; 20: 77-82.
34. Gadjeva V, Lazarova G, Zheleva A. Spin labeled antioxidants protect bacteria against the toxicity of alkylating antitumor drug CCNU. Toxicol. Lett.2003; 144: 289-294.
35. Zheleva A, Tolekova A, Goicheva P. Determination of LD50 of potential antitumor agent SLCNUgly and its effect on antioxidant enzyme defense in vivo. Trakia J Sci. 2008; 6(2): 49-53.
36. Gannon MC, Nuttall JA, and Nuttall FQ. Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal. Am. J. Clin. Nutr. 2002; 76: 1016–1022.
37. Keana JF, Pou S, Rosen GM. Nitroxides as a potentioal contrast enhancing agents for MRI application: influence of structure on the rate of reduction by rat hepatocytes, whole liver homogenate, subcellular fractions, and ascorbate. Magn Reson Med. 1987; 5: 525-536.
38. Zhelev Z, Bakalova R, Aoki I, Matsumoto K, Gadjeva V, Anzai K, Kanno I. Nitroxyl radicals for labeling of conventional therapeutics and noninvasive magnetic resonance imaging of their permeability for blood-brain barrier: relationship between structure, blood clearance, and MRI signal dynamic in the brain. Mol Pharm. 2009; 6: 504-512.
39. Hyodo F, Chuang KH, Goloshevsky AG, Sulima A, Griffiths GL, Mitchell JB, Koretsky AP, Krishna MC. Brain redox imaging using blood - brain barrier - permeable nitroxide MRI contrast agent. J Cereb Blood Flow Metab. 2008; 28: 1165-1174.
40. Hahn SM, Krishna CM, Mitchell JB. New directions for free radical cancer research and medical applications. Adv Exp Med Biol. 1994; 366: 241- 251.
41. Wilcox CS. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol. Ther. 2010; 126(2): 119-145.
42. Hahn SM, Krishna CM, Samuni A, Cuscela DO, Johnstone P, Mitchell JB. Potential use of nitroxides in radiation oncology. Cancer Res. 2004; 54: 2006-2010.
43. Sano H, Naruse M, Matsumoto K, Oi T, Utsumi H. A new nitroxyl-probe with high retention in the brain and its application for brain imaging. Free Radic Biol Med. 2000; 28: 959-969.
44. Zhelev Z, Matsumoto K, Gadjeva V, Bakalova R, Aoki I, Zheleva A, Anzai K. EPR signal reduction kinetic of several nitroxyl derivatives in blood in vitro and in vivo. Gen Physiol Biophys. 2009; 28: 356-362.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Karamalakova Y,Chuttani K,Sharma R,Gadjeva V,Gadjeva A,Mishra A. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Deepti Sureka Mummidi1,*,Dharmendra Dugar1,±, Ranjit K Mishra1,¥,
Jatasankar Mohapatra1,±, Tim Houghton T1
Affiliation:
1P.G Student, 1±Professor, 1¥Professor and HOD Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to
* Dr. Deepti Sureka Mummidi.
P.G Student, Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address: Flat no A108, Gatikrushna lagoon, near megheswar temple, Tankapani road, Bhubaneswar, odisha, India 751018.
Article citation:
Mummidi DS,Dugar D,Mishra RK, Mohapatra JS, Houghton T. Clinicopathological study: management Of diabetic foot and its Complications. J Pharm Biomed Sci. 2015; 05(04):308-311. Available at www.jpbms.info
ABSTRACT:
Diabetes is a lifelong problem, and the incidence of diabetic foot complications increases with age and duration of the disease. Ulceration, infection, gangrene, and amputation are significant complications of the disease. Diabetic foot infections are frequently polymicrobial in nature. Hyperglycemia, impaired immunologic responses, neuropathy, and peripheral arterial disease are the major predisposing factors leading to limb-threatening diabetic foot infections.
Objectives of the study: To understand the pathology of diabetic foot and relative distribution of this condition according to age, sex, among diabetic patients. To study the benefit and outcome of the different treatment modalities for diabetic foot
Methods: This study was conducted comprising of 100 patients of diabetic foot in the department of general surgery at Hitech medical college and hospital, Bhubaneswar, Odisha, during the period of Jan 2013 to Jun 2014.
Results: Commonest presenting lesion was ulcers (44%), followed by gangrene (24%) and cellulitis (20%). Commonest site of the lesion was dorsum of the foot (32%), followed by fore foot (28%), and toes (22%). Trivial trauma is the initiating factor in more than half of the cases. More than half of the patients 82% had infection. Most common microorganism grown from culture was staphylococcus aureus (30%), 28(28%) patients were treated with wound debridement, 18(18%) patients underwent major amputation. Prognosis was good in 72(72%) patients. 2(2%) patient died due to septicemia.
Conclusion: Diabetic patients at risk for foot lesions must be educated about risk factors. The multidisciplinary team approach to diabetic foot disorders has been demonstrated as the optimal method to achieve favorable rates of limb salvage in the high-risk diabetic patient. Infection in a diabetic foot is potentially limb-threatening and always requires urgent diagnostic and therapeutic attentions.
KEYWORDS: Diabetes; foot ulcers; neuropathy; ischemia.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
REFERENCES
1.Reiber GE. Epidemiology of foot ulcers and amputation in the diabetic foot. Bowker JH, Pfeifer MA, eds. The diabetic foot, 6th ed. st. Louis, Mo:Mosby Inc;2001:13-32.
2.Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhy N, Reiber GE, et al. Incidence, outcomes and cost of foot ulcers in patients with diabetes.diabetes care 2009; 22:382-7.
3.Hilary King, Ronald E. Aubert, William H. Herman. Global Burden of Diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
4.Lt Gen SR Mehta, VSM, Col AS Kashyap, Lt Col S Das. Diabetes Mellitus in India: The Modern Scourge. MJAFI2009; 65 : 50-54.
5.Wheel Lock, FC. Jr et al: Annals of surgery, 99: 776: 1969.
6.Mayfield, Jennifer, A., et al 1996: "A foot risk classification system to predict diabetic amputation in Pima Indians". Diabetes care 1996 July, 704- 709pp.
7.Apelqvist J, Larsson J, Agard C. Long term prognosis for diabetic patients with foot ulcers. JInt Med 1993; 233:485-491.
8.Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176:5S-10S.
Source of support: None
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Mummidi DS,Dugar D,Mishra RK, Mohapatra JS, Houghton T. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:
FENG Xiaofei1,†, LI Linlin2,†, LUO Rui1, HE Ying1, LIANG Wenli1, XU Zhenxia1, ZHAO Wen1,NI Peihong3, LI Sha1,*
Affiliation:
1 Department of Pharmaceutics, College of Pharmacy,Jinan University, Guangzhou 510632, China
2 The Fourth People's Hospital of Chenzhou, Chenzhou 423000, Hunan, China
3Guangzhou Toplink Gene Bio-Engineering Co. Ltd., Guangzhou 510000, China
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Pharmaceutics, College of Pharmacy,Jinan University, Guangzhou 510632, China
2.The Fourth People's Hospital of Chenzhou, Chenzhou 423000, Hunan, China
3.Guangzhou Toplink Gene Bio-Engineering Co. Ltd.,Guangzhou 510000, China
Authors contributions: Both FENG Xiaofei and LI Linlin contributed equally to this work.
Address reprint requests to
LI Sha.
Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
Article citation: Feng X, LI L, Luo R, HE Y, Liang W,Xu Z, et al. Preparation and drug release behavior of Diclofenac Sodium hydrophilic matrix tablets. J Pharm Biomed Sci.2015; 05(04):365-371. Available at www.jpbms.info
ABSTRACT: Objectives: Diclofenac sodium, an arthritis drug of wide clinic use, shows good solubility, quick absorption and short half life, and is susceptible to generate high blood concentration fluctuation. In order to improve the weakness, hydrophilic matrix tablets of DS were prepared by using hydroxypropylmethyl cellulose (HPMC) as matrix material. The tablets were prepared by direct compression, and the polymer sort and proportion, the amount of microcrystalline cellulose (MCC), and the hardness of tablets were screened to optimize the formulation and process. The results showed that the ratio of matrix material to drug was the chief factor influencing the release behavior of DS from hydrophilic matrix tablets. With the decrease of matrix material, the drug release became faster and more complete.
The addition of MCC changed the release of DS to some extent, especially reducing the burst release within 2 h. The influence of pressure was not so much great that distinct difference in drug release was only observed when the pressure was too high to be 11.5 kg. The optimal matrix tablets of DS showed no apparent burst release, and less than 30% of drug was released at 2 h. The drug continuously released slowly to an accumulative release of 94.3% at 12 h. The Higuchi equation and Ritger-Peppas equation fitted the drug release data well, which indicated a typical sustained release of DS controlled by both diffusion and erosion.
KEYWORDS: Diclofenac Sodium; Hydroxypropylmethyl cellulose; Hydrophilic matrix tablet; Sustained release.
Short communication
Senthilkumar Rajagopal*, Supraj Raja Sangam, Shubham Singh
Affiliation:
Department of Zoology, Nizam College, Hyderabad, Telangana, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Zoology, Nizam College, Hyderabad, Telangana, India
Address reprint requests to
* Dr.R.Senthilkumar, Ph.D.,
DBT-Ramalingaswami Re-entry Fellow,
Dept of Zoology, Nizam College, Hyderabad, Telangana, India
Article citation:
Rajagopal S, Sangam SR, Singh S. Contribution of Protein Kinase C (PKC) in the modulation of Voltage gated Calcium Channels. J Pharm Biomed Sci. 2015;05(04):351-354. Available at www.jpbms.info
ABSTRACT:
High voltage-gated calcium (CaV) channels are the major source for Ca2+ influx that underlies Ca2+ -dependent response in excitable cells. Protein kinase C (PKC) is families of protein kinases enzymes that are play important roles in several signal transduction cascades. Ca2+, CaV channels and PKC are involved in the processes of pain, insulin secretion, glucose homeostasis, smooth muscle physiology, response to neuro-chemicals, receptor sensitization, in modulating membrane structure events, in mediating immune response, in regulating cell growth, and in learning and memory. The identification of the roles of these proteins will provide us significant knowledge for the understanding of the complexity of the ion channel physiology and regulation of many diseases. In this short communications, we discuss the contribution of PKC in the modulation of calcium channels in Xenopus oocytes model.
KEYWORDS: Acetyl-β-methylcholine; insulin; pain; phorbol-12-myristate-13-acetate;phosphorylation sites; Xenopus oocytes.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
REFERENCES
1.Dolphin, A. Beta subunits of voltage-gated calcium channels. J Bioenerg Biomembr, 2003; 35:599-620.
2.Dolphin, A. A short history of voltage-gated calcium channels. Br J Pharmacol, 2006; 147: S56-S62.
3.Catterall, WA. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett, 2010; 486: 107-116.
4.Hamid, J., Nelson, D., Spaetgens, R., Dubel, S., et al., Identification of an interaction center for cross-talk between protein kinase C and G protein modulation of N-type calcium channels. J Biol Chem, 1999; 274: 6195-9202.
5.Melliti, K, Meza, U., Adams, B. Muscarinic stimulation of α1E Ca channels is selectively blocked by the effector antagonist function of RGS2 and phospholipase C-β1. J Neurosci, 2000; 20: 7167-7173.
6.Zuhlke, R., Reuter, H. Ca2+ -sensitive inactivation of L-type Ca2+ channels depends on multiple cytoplasmic amino acid sequence of the α1C subunit. Proc Natl Acad Sci USA, 1998; 95: 3287-3294.
7.Walker, D, DeWard, M. Subunit interaction sites in voltage dependent Ca2+ channels: role in channel function. Trends Neuro Sci, 1998; 21:148-154.
8.Jones, L., Wei, S-K., Yue, D. Mechanism of auxiliary subunit modulation of neuronla alpha 1E calcium channels. J Gen Physiol, 1998; 112:125-143.
9.Coderre, T., Katz, J., Vaccarino, A., Melzack, R. Contribution of central neuroplasitcity to pathological pain: review of clinical and experimental evidence. Pain, 1993; 52: 259-285.
10.Yaksh, TL. Central Pharmacology of nociceptive transmission. In:Wall, PD., Melzack, R. (Eds). Text book of pain. Churchill Living Stone, London, UK, 1999:253-308.
11.Catterall, WA. Voltage gated calcium channels. Cold Spring Harb Perspect Biol 2011; 3: a003947; 1-25.
12.Newton, AC., Johnson, J. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochem Biophys Acta, 1998; 1376:155-172.
13.Newton, AC. Diacylglycerol’s affair with protein kinase C turns 25. Trends Pharmacol Sci, 2004; 25: 175-177.
14.Newton, AC. protein kinase C: poised to signal. Am J Physiol; Endocrinol Metab, 2010; 298(3):E395-E402.
15.Fang, H., Patanavanich, S., Rajagopal, S., Yi, X., et al., Inhibitory role of Ser-425 of the α1 2.2 subunit in the enhancement of CaV2.2 currents by phorbol-12-myristate, 13-acetate. J Biol Chem, 2006;281(29): 20011-20017.
16.Rajagopal, S., Fang, H., Patanavanich, S., Sando, JJ., Kamatchi, GL. Protein kinase C isozyme-specific potentiation of expressed CaV2.3 currents by acetyl-β-methylcholine and phorbol-12-myristate, 13 acetate. Brain Res, 2008; 210: 1-10.
17.Kamatchi, GL., Franke, R., Lynch, C III., Sando, JJ. Identification of Sites responsible for potentiation of type 2.3 calcium currents by acetyl-β-methylcholine. J Biol Chem, 2004; 279(6):4102–4109.
18.Fang, H., Ruthie, F., Saharat, P., et al., Role of α1 2.3 subunit I–II linker sites in the enhancement of CaV2.3 currents by phorbol 13-myristate 13-acetate. J Biol Chem, 2005; 280(25):23559–23565.
19.Rajagopal, S., Fang, H., Oronce, CIA., Jhaveri, S., et al., Site-specific regulation of CaV 2.2 channels by protein kinase c Isozymes II and. Neurosci, 2009; 159: 618-628.
20.Rajagopal, S., Fang, H., Lynch, C., III et al., Formalin -induced–short and long-term modulation of CaV currents expressed in Xenopus oocytes: An in vitro cellular model for formalin–induced pain. Basic Clin Pharmacol Toxicol, 2010; 106: 338-347.
21.Rajagopal, S., Fang, H., Lynch, C III., et al., Effects of Isoflurane on the Expressed Cav2.2 currents in Xenopus oocytes Depend on the Activation of Protein Kinase C and its Phosphorylation Sites in the 12.2 Subunits. Neurosci, 2011; 182: 232-240.
22.Rajagopal, S., Fields, BL., Burton, BK., et al., Inhibition of Protein kinase C response of voltage-gated calcium (CaV) 2.2 channels expressed in Xenopus oocytes by CaVβ subunits. Neurosci, 2014; 280: 1-9.
23.Rajagopal, S, Fields, BL., Kamatchi, GL. Contribution of Protein Kinase C Isozyme in the Stimulation of Insulin Secretion by the Inhibition of CaVβ subunits. Endocri, 2014; 47(2):463-471.
24.Yang, SN., Berggren, PO. The role of voltage-gated calcium channels in pancreatic beta-cell physiology and pathophysiology. Endocr Rev, 2006; 27: 621–676.
25.Kamatchi, GL., Tiwari, S., Chan, C., et al., Distinct regulation of expressed calcium channel 2.3 in Xenopus oocytes by direct or indirect activation of protein kinase C. Brain Res, 2003; 968:227–237.
26.Hell, JW., Westenbroek, RE., Warner, C., Ahlijanian, M.K., et al., Identification and differential sub cellular localization of the neuronal class C and class D L-type calcium channel α1 subunits. J Cell Biol, 1993; 123: 949-962.
27.Yokoyama, CT., Westenbroek, RE., Hell, JW., et al., Biochemical properties and sub cellular distribution of the neuronal class E calcium channel α1 subunit. J Neurosci, 1995:15:6419–6432.
Source of support: This work was supported by Department of Biotechnology, Ministry of Science & Technology, and Government of India to R.S.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Rajagopal S, Sangam SR, Singh S. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article
Zuo Ling1,2,4, Zhang Bei-bei1,2, Bei Yu2, Zhang Min-jing2, Pang Ji-yan3, Zhang Qi-hao2, Su Zhi-jian2, Huang Ya-dong2, Yang Hong-tu4, Xiang Qi1,2*
Affiliation:
1Department of Pharmacy, Jinan University, Guangzhou, People’s Republic of China
2Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangdong, People’s Republic of China
3School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou, People’s Republic of China
4The People’s Hospital of Shenzhen City, Shenzhen, People’s Republic of China
The name of the department(s) and institution(s) to which the work should be attributed:
1. Department of Pharmacy, Jinan University, Guangzhou, People’s Republic of China
2. Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangdong, People’s Republic of China
3. The People’s Hospital of Shenzhen City, Shenzhen, People’s Republic of China
4. School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou, People’s Republic of China
Address reprint requests to
Xiang Qi
1. Department of Pharmacy, Jinan University, Guangzhou, People’s Republic of China
2. Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, Guangdong, People’s Republic of China or at
Tel +86 20 8556 3234
Fax +86 20 8556 5109
Article citation: Zuo L, Bie Y, Zhang BB, Zhang MJ, Pang JY, Zhang QH, et al. Serum amino acids profiling in NAFLD mice. J Pharm Biomed Sci. 2015; 05(04):355-364. Available at www.jpbms.info
ABSTRACT:
Objectives: To detect the variation of serum amino acids in control and nonalcoholic fatty liver disease (NAFLD) mice by PITC pre-column derivatization HPLC, and further explore the potential biomarkers associated with the development of NAFLD using metabolism profiling analysis. Methods: Male C57BL/6J mice were fed with high fat and high fructose diet, after 8 weeks, serum samples of control and model mice were collected. Serum biochemical parameter and liver histopathology were examined, and then metabolic profile was further analyzed using PITC pre-column derivatization HPLC. Result: Levels of serum and hepatic biochemical parameter and liver histopathology verified the NAFLD model successfully. The metabolism profile of NAFLD model mice was significantly different from that of the control mice. Conclusion: Pattern recognition method demonstrated that there were significant differences in the five amino acids markers (glutamic acid, glycine, methionine, isoleucine, valine) between the control and NAFLD mice. Amino acids metabolism profile combined with pattern recognition technology may reflect to a certain extent the metabolism changes of NAFLD mice. It also provided the potential scientific and clinic value for further study of NAFLD.
KEYWORDS: HPLC; amino acid; nonalcoholic fatty liver disease.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
ACKNOWLEDGEMENTS:
The work was supported by grants of the National Natural Science Foundation of China (No. 21172271), Youth fund project of national natural science fund (No.81202454), Major Scientific and Technological Special Project of Administration of Ocean and Fisheries of Guangdong Province (A201301C08), and from Natural Science Foundation of Guangdong Provincial, China (No. 2011020001231).
REFERENCES
1.Han D, Hanawa N, Saberi B, Kaplowitz N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006;291(1):G1-G7.
2.Fakurazi S, Hairuszah I, Nanthini U. Moringa oleifera Lam prevents acetaminophen induced liver injury through restoration of glutathione level. Food and chemical toxicology. 2008;46(8):2611-5.
3.Kharbanda KK, editor. Alcoholic liver disease and methionine metabolism. Seminars in liver disease; 2009.
4.Dejong CH, van de Poll MC, Soeters PB, Jalan R, Damink SWO. Aromatic amino acid metabolism during liver failure. The Journal of nutrition. 2007;137(6):1579S-85S.
5.Quan HY, Kim do Y, Kim SJ, Jo HK, Kim GW, Chung SH. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochemical pharmacology. 2013;85(9):1330-40.
6.Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Archiv : an international journal of pathology. 2004;444(1):3-12.
7.Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004;2(12):1048-58.
8.Avalueva EB, Tkachenko EI, Skazyvaeva EV, Ivanov SV, Orishak EA, Lapinskii IV. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology. 2013(11):26-30.
9.Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic medicine : a journal of the British Diabetic Association. 2005;22(9):1141-5.
10.Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in lipid research. 2009;48(1):1-26.
11.Jacome-Sosa MM, Borthwick F, Mangat R, et al. Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome. The Journal of nutritional biochemistry. 2014;25(7):692-701.
12.Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art in 2015. Frontiers in bioengineering and biotechnology. 2015;3:23.
13.Antonucci R, Pilloni MD, Atzori L, Fanos V. Pharmaceutical research and metabolomics in the newborn. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2012;25(Suppl 5):22-6.
14.Cox DG, Oh J, Keasling A, Colson KL, Hamann MT. The utility of metabolomics in natural product and biomarker characterization. Biochimica et biophysica acta. 2014;1840(12):3460-74.
15.Laiakis EC, Morris GAJ, Albert J. Fornace J, Howie SRC. Metabolomic Analysis in Severe Childhood Pneumonia in The Gambia, West Africa: Findings from a Pilot Study. PloS one. 2010;5(9):: e12655.
16.Nkomo MM, Katerere DD, Vismer HH, et al. Fusarium inhibition by wild populations of the medicinal plant Salvia africana-lutea L. linked to metabolomic profiling. BMC Complementary and Alternative Medicine. 2014;14(2):377-83.
17.Schmidt MM, Dringen R. Glutathione (GSH) Synthesis and Metabolism. Advances in Neurobiology. 2012.
18.Gentric G, Maillet V, Paradis V, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. The Journal of clinical investigation. 2015;125(3):981-92.
19.Layman DK, Shiue H, Sather C, Erickson DJ, Baum J. Increased dietary protein modifies glucose and insulin homeostasis in adult women during weight loss. The Journal of nutrition. 2003;133(2):405-10.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Zuo L, Bie Y, Zhang BB, Zhang MJ, Pang JY, Zhang QH, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.